Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Lung Cancer

Free Subscription Articles published in Clin Cancer Res Retrieve available abstracts of 161 articles: HTML format

Single Articles

August 2022
1. HIATT JB, Sandborg H, Garrison SM, Arnold HU, et al
   Inhibition of LSD1 with bomedemstat sensitizes small cell lung cancer to immune checkpoint blockade and T cell killing.
   Clin Cancer Res. 2022 Aug 3. pii: 707373. doi: 10.1158/1078-0432.CCR-22-1128.
   PubMed     Abstract available
   
   
   
2. WEI S, Gao X, Tang M, Li J, et al
   Perioperative ctDNA-Based MRD Detection in NSCLC- Letter.
   Clin Cancer Res. 2022;28:3400.
   PubMed    
   
   
   
3. XIA L, Chen W, Liu L
   Perioperative ctDNA-Based MRD Detection in NSCLC-Response.
   Clin Cancer Res. 2022;28:3401.
   PubMed    
   
   
   July 2022
4. HUNIHAN L, Zhao D, Lazowski H, Li M, et al
   RASGRF1 Fusions Activate Oncogenic RAS Signaling and Confer Sensitivity to MEK Inhibition.
   Clin Cancer Res. 2022;28:3091-3103.
   PubMed     Abstract available
   
   
   
5. BARLESI F, Tomasini P, Karimi M, Michiels S, et al
   Comprehensive genome profiling in patients with metastatic non-small cell lung cancer: the precision medicine phase 2 randomized SAFIR02-Lung trial.
   Clin Cancer Res. 2022 Jul 8. pii: 706925. doi: 10.1158/1078-0432.CCR-22-0371.
   PubMed     Abstract available
   
   
   
6. FEBRES ALDANA CA, Chang JC, Ptashkin R, Wang Y, et al
   Rb tumor suppressor in small cell lung cancer: Combined genomic and immunohistochemical analysis with a description of a distinct Rb-proficient subset.
   Clin Cancer Res. 2022 Jul 6. pii: 706889. doi: 10.1158/1078-0432.CCR-22-1115.
   PubMed     Abstract available
   
   
   June 2022
7. SCHOENFELD AJ, Rizvi HA, Memon D, Shaverdian N, et al
   Systemic and oligo-acquired resistance to PD-(L)1 blockade in lung cancer.
   Clin Cancer Res. 2022 Jun 29. pii: 705289. doi: 10.1158/1078-0432.CCR-22-0657.
   PubMed     Abstract available
   
   
   
8. AKAMATSU H, Teraoka S, Takamori S, Miura S, et al
   Nivolumab Retreatment in Non-Small Cell Lung Cancer Patients Who Responded to Prior Immune Checkpoint Inhibitors and Had ICI-Free Intervals (WJOG9616L).
   Clin Cancer Res. 2022 Jun 28:OF1-OF7. doi: 10.1158/1078-0432.CCR-22-0602.
   PubMed     Abstract available
   
   
   
9. YANG JC, Ohe Y, Chiu CH, Ou X, et al
   Osimertinib plus Selumetinib in EGFR-Mutated Non-Small Cell Lung Cancer After Progression on EGFR-TKIs: A Phase Ib, Open-Label, Multicenter Trial (TATTON Part B).
   Clin Cancer Res. 2022 Jun 23:OF1-OF10. doi: 10.1158/1078-0432.CCR-21-4329.
   PubMed     Abstract available
   
   
   
10. GUAN S, Chen X, Chen Y, Xie W, et al
    FOXM1 variant contributes to gefitinib resistance via activating wnt/beta-catenin signal pathway in non-small cell lung cancer patients.
    Clin Cancer Res. 2022 Jun 13. pii: 704872. doi: 10.1158/1078-0432.CCR-22-0791.
    PubMed     Abstract available
    
    
    
11. MURCIANO-GOROFF YR, Harada G, Drilon A
    An Ascendant Challenge: Central Nervous System Metastases in ALK+ Lung Cancers.
    Clin Cancer Res. 2022;28:2477-2479.
    PubMed     Abstract available
    
    
    
12. TAKEMOTO A, Takagi S, Ukaji T, Gyobu N, et al
    Targeting Podoplanin for the Treatment of Osteosarcoma.
    Clin Cancer Res. 2022;28:2633-2645.
    PubMed     Abstract available
    
    
    
13. ROCHA P, Zhang J, Laza-Briviesca R, Cruz-Bermudez A, et al
    Distinct Immune Gene Programs Associated with Host Tumor Immunity, Neoadjuvant Chemotherapy, and Chemoimmunotherapy in Resectable NSCLC.
    Clin Cancer Res. 2022;28:2461-2473.
    PubMed     Abstract available
    
    
    
14. TSENG D, Gainor JF
    Searching for Synergy: Chemotherapy and Checkpoint Inhibitors.
    Clin Cancer Res. 2022;28:2206-2208.
    PubMed     Abstract available
    
    
    
15. PATIL T, Bunn PA
    Adjuvant Osimertinib in EGFR-Mutant Early-Stage NSCLC: Does HRQoL Influence Decisions?
    Clin Cancer Res. 2022;28:2204-2205.
    PubMed     Abstract available
    
    
    
16. CHOUDHURY AD, Higano CS, de Bono JS, Cook N, et al
    A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kbeta/delta, in Patients with Advanced Solid Tumors.
    Clin Cancer Res. 2022;28:2257-2269.
    PubMed     Abstract available
    
    
    
17. AKINBORO O, Larkins E, Pai-Scherf LH, Mathieu LN, et al
    FDA Approval Summary: Pembrolizumab, Atezolizumab, and Cemiplimab-rwlc as Single Agents for First-Line Treatment of Advanced/Metastatic PD-L1-High NSCLC.
    Clin Cancer Res. 2022;28:2221-2228.
    PubMed     Abstract available
    
    
    
18. JUNG HA, Park S, Choi YL, Lee SH, et al
    Continuation of Pembrolizumab with Additional Chemotherapy after Progression with PD-1/PD-L1 Inhibitor Monotherapy in Patients with Advanced NSCLC: A Randomized, Placebo-Controlled Phase II Study.
    Clin Cancer Res. 2022;28:2321-2328.
    PubMed     Abstract available
    
    
    May 2022
19. AKAMATSU H, Teraoka S, Takamori S, Miura S, et al
    Nivolumab retreatment in non-small cell lung cancer patients who responded to prior immune-checkpoint inhibitors and had ICI-free intervals (WJOG9616L).
    Clin Cancer Res. 2022 May 26. pii: 699251. doi: 10.1158/1078-0432.CCR-22-0602.
    PubMed     Abstract available
    
    
    
20. YANG JC, Ohe Y, Chiu CH, Ou X, et al
    Osimertinib plus selumetinib in EGFR-mutated, non-small cell lung cancer after progression on EGFR-TKIs: A Phase 1b, open-label, multicenter trial (TATTON Part B).
    Clin Cancer Res. 2022 May 26. pii: 699247. doi: 10.1158/1078-0432.CCR-21-4329.
    PubMed     Abstract available
    
    
    
21. KOMMALAPATI A, Mansfield AS
    Trials, tribunals, and opportunities for lung cancer KRASG12C brain metastases.
    Clin Cancer Res. 2022 May 24. pii: 699172. doi: 10.1158/1078-0432.CCR-22-1137.
    PubMed     Abstract available
    
    
    
22. FRIZZIERO M, Kilgour E, Simpson KL, Rothwell DG, et al
    Expanding Therapeutic Opportunities for Extrapulmonary Neuroendocrine Carcinoma.
    Clin Cancer Res. 2022;28:1999-2019.
    PubMed     Abstract available
    
    
    
23. MOORTHI S, Berger AH
    All about that Ras: Novel fusion drives Ras pathway activation in lung cancer.
    Clin Cancer Res. 2022 May 5. pii: 696314. doi: 10.1158/1078-0432.CCR-22-0736.
    PubMed     Abstract available
    
    
    
24. TON TGN, Pal N, Trinh H, Mahrus S, et al
    Replication of overall survival, progression-free survival, and overall response in chemotherapy arms of non-small cell lung cancer trials using real-world data.
    Clin Cancer Res. 2022 May 5. pii: 696304. doi: 10.1158/1078-0432.CCR-22-0471.
    PubMed     Abstract available
    
    
    April 2022
25. SONG L, Xiong H, Li J, Liao W, et al
    Correction: Sphingosine Kinase-1 Enhances Resistance to Apoptosis through Activation of PI3K/Akt/NFkappaB Pathway in Human Non-small Cell Lung Cancer.
    Clin Cancer Res. 2022;28:1740.
    PubMed    
    
    
    
26. NAKAJIMA EC, Drezner N, Li X, Mishra-Kalyani PS, et al
    FDA Approval Summary: Sotorasib for KRAS G12C-Mutated Metastatic NSCLC.
    Clin Cancer Res. 2022;28:1482-1486.
    PubMed     Abstract available
    
    
    
27. SABARI JK, Velcheti V, Shimizu K, Strickland MR, et al
    Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data From Patients With KRASG12C-Mutant Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2022 Apr 11. pii: 694212. doi: 10.1158/1078-0432.CCR-22-0383.
    PubMed     Abstract available
    
    
    
28. DEMETRI GD, De Braud F, Drilon A, Siena S, et al
    Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors.
    Clin Cancer Res. 2022;28:1302-1312.
    PubMed     Abstract available
    
    
    March 2022
29. ROSNER S, Spira AI
    Has the Enemy "MET" Its Match? Subgroup Analysis Results from VISION Study.
    Clin Cancer Res. 2022;28:1055-1057.
    PubMed     Abstract available
    
    
    
30. LE X, Sakai H, Felip E, Veillon R, et al
    Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice.
    Clin Cancer Res. 2022;28:1117-1126.
    PubMed     Abstract available
    
    
    
31. DZIADZIUSZKO R, Peters S, Mok T, Camidge DR, et al
    Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced ALK+ Non-small Cell Lung Cancer in the Global Phase III ALEX Trial.
    Clin Cancer Res. 2022 Mar 11. pii: 681795. doi: 10.1158/1078-0432.CCR-21-2840.
    PubMed     Abstract available
    
    
    
32. CHIAPPORI AA, Creelan B, Tanvetyanon T, Gray JE, et al
    Phase I study of taminadenant (PBF509/NIR178), an adenosine 2A receptor antagonist, with or without spartalizumab, in patients with advanced non-small cell lung cancer.
    Clin Cancer Res. 2022 Mar 7. pii: 682078. doi: 10.1158/1078-0432.CCR-21-2742.
    PubMed     Abstract available
    
    
    
33. HAYASHI H, Sugawara S, Fukuda Y, Fujimoto D, et al
    A Randomized Phase II Study Comparing Nivolumab with Carboplatin-Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L).
    Clin Cancer Res. 2022;28:893-902.
    PubMed     Abstract available
    
    
    February 2022
34. LEE JK, Hazar-Rethinam M, Decker B, Gjoerup O, et al
    The Pan-Tumor Landscape of Targetable Kinase Fusions in Circulating Tumor DNA.
    Clin Cancer Res. 2022;28:728-737.
    PubMed     Abstract available
    
    
    
35. MAJEED S, Aparnathi MK, Nixon KCJ, Venkatasubramanian V, et al
    Targeting the ubiquitin-proteasome system using the UBA1 inhibitor TAK-243 is a potential therapeutic strategy for small cell lung cancer.
    Clin Cancer Res. 2022 Feb 14. pii: 1078-0432.CCR-21-0344.
    PubMed     Abstract available
    
    
    
36. MAJEED S, Aparnathi MK, Nixon KCJ, Venkatasubramanian V, et al
    Targeting the ubiquitin-proteasome system using the UBA1 inhibitor TAK-243 is a potential therapeutic strategy for small cell lung cancer.
    Clin Cancer Res. 2022 Feb 11. pii: 681703. doi: 10.1158/1078-0432.CCR-21-0344.
    PubMed     Abstract available
    
    
    
37. NAKAJIMA EC, Vellanki PJ, Larkins E, Chatterjee S, et al
    FDA Approval Summary: Nivolumab in Combination with Ipilimumab for the Treatment of Unresectable Malignant Pleural Mesothelioma.
    Clin Cancer Res. 2022;28:446-451.
    PubMed     Abstract available
    
    
    January 2022
38. CHOW LQM, Barlesi F, Bertino EM, van den Bent MJ, et al
    ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients With ALK-Positive Non-Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges.
    Clin Cancer Res. 2022 Jan 28. pii: 1078-0432.CCR-21-1838.
    PubMed     Abstract available
    
    
    
39. RICCIUTI B, Son J, Okoro JJ, Mira A, et al
    Comparative analysis and isoform-specific therapeutic vulnerabilities of KRAS mutations in non-small cell lung cancer.
    Clin Cancer Res. 2022 Jan 28. pii: 1078-0432.CCR-21-2719.
    PubMed     Abstract available
    
    
    
40. TULLY KM, Tendler S, Carter LM, Sharma SK, et al
    Radioimmunotherapy Targeting Delta-like Ligand 3 in Small Cell Lung Cancer exhibits antitumor efficacy with low toxicity.
    Clin Cancer Res. 2022 Jan 19. pii: 1078-0432.CCR-21-1533.
    PubMed     Abstract available
    
    
    
41. SUZUKI S, Yonesaka K, Teramura T, Takehara T, et al
    Correction: KRAS Inhibitor Resistance in MET-Amplified KRAS (G12C) Non-Small Cell Lung Cancer Induced By RAS- and Non-RAS-Mediated Cell Signaling Mechanisms.
    Clin Cancer Res. 2022;28:428.
    PubMed    
    
    
    
42. MATHIEU LN, Larkins E, Akinboro O, Roy P, et al
    FDA Approval Summary: Capmatinib and Tepotinib for the Treatment of Metastatic NSCLC Harboring MET Exon 14 Skipping Mutations or Alterations.
    Clin Cancer Res. 2022;28:249-254.
    PubMed     Abstract available
    
    
    
43. MAJEM M, Goldman JW, John T, Grohe C, et al
    Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer who underwent Adjuvant Osimertinib in the phase III ADAURA trial.
    Clin Cancer Res. 2022 Jan 10. pii: 1078-0432.CCR-21-3530.
    PubMed     Abstract available
    
    
    
44. GAO Y, Paivinen P, Tripathi S, Domenech-Moreno E, et al
    Inactivation of AMPK Leads to Attenuation of Antigen Presentation and Immune Evasion in Lung Adenocarcinoma.
    Clin Cancer Res. 2022;28:227-237.
    PubMed     Abstract available
    
    
    
45. LEE JC, Green MD, Huppert LA, Chow C, et al
    The Liver-Immunity Nexus and Cancer Immunotherapy.
    Clin Cancer Res. 2022;28:5-12.
    PubMed     Abstract available
    
    
    December 2021
46. YONESAKA K, Tanizaki J, Maenishi O, Haratani K, et al
    HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2021 Dec 17. pii: 1078-0432.CCR-21-3359.
    PubMed     Abstract available
    
    
    
47. JIN Y, Chen Y, Tang H, Hubert SM, et al
    Activation of PI3K/AKT pathway is a potential mechanism of treatment resistance in small cell lung cancer.
    Clin Cancer Res. 2021 Dec 17. pii: 1078-0432.CCR-21-1943.
    PubMed     Abstract available
    
    
    
48. DI NOIA V, Pimpinelli F, Renna D, Barberi V, et al
    Immunogenicity and Safety of COVID-19 Vaccine BNT162b2 for Patients with Solid Cancer: A Large Cohort Prospective Study from a Single Institution.
    Clin Cancer Res. 2021;27:6815-6823.
    PubMed     Abstract available
    
    
    
49. HANNAN R, Mohamad O, Diaz de Leon A, Manna S, et al
    Outcome and Immune Correlates of a Phase II Trial of High-Dose Interleukin-2 and Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma.
    Clin Cancer Res. 2021;27:6716-6725.
    PubMed     Abstract available
    
    
    
50. LEE CJ, Schoffski P, Modave E, van Wezel T, et al
    Comprehensive Molecular Analysis of Inflammatory Myofibroblastic Tumors Reveals Diverse Genomic Landscape and Potential Predictive Markers for Response to Crizotinib.
    Clin Cancer Res. 2021;27:6737-6748.
    PubMed     Abstract available
    
    
    November 2021
51. XIA L, Mei J, Kang R, Deng S, et al
    Perioperative ctDNA-based Molecular Residual Disease Detection for Non-Small Cell Lung Cancer: A Prospective Multicenter Cohort Study (LUNGCA-1).
    Clin Cancer Res. 2021 Nov 29. pii: 1078-0432.CCR-21-3044.
    PubMed     Abstract available
    
    
    
52. SONG Z, Lv D, Chen SQ, Huang J, et al
    Pyrotinib in Patients with HER2-Amplified Advanced Non-Small Cell Lung Cancer: A Prospective, Multicenter, Single-Arm Trial.
    Clin Cancer Res. 2021 Nov 9. pii: 1078-0432.CCR-21-2936.
    PubMed     Abstract available
    
    
    
53. ZHOU Q, Wu L, Hu P, An T, et al
    A novel third generation EGFR tyrosine kinase inhibitor Abivertinib for EGFR T790M mutant Non-Small Cell Lung Cancer: a multicenter phase1/2 study.
    Clin Cancer Res. 2021 Nov 5. pii: 1078-0432.CCR-21-2595.
    PubMed     Abstract available
    
    
    
54. BISWAS T, Dowlati A, Kunos CA, Pink JJ, et al
    Adding Base Excision Repair Inhibitor TRC102 to standard Pemetrexed-Platinum-Radiation in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer: Results of a phase I trial.
    Clin Cancer Res. 2021 Nov 5. pii: 1078-0432.CCR-21-2025.
    PubMed     Abstract available
    
    
    
55. CASARRUBIOS M, Cruz-Bermudez A, Nadal E, Insa A, et al
    Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy.
    Clin Cancer Res. 2021;27:5878-5890.
    PubMed     Abstract available
    
    
    
56. CHUA KP, Teng YHF, Tan AC, Takano A, et al
    Integrative Profiling of T790M-Negative EGFR-Mutated NSCLC Reveals Pervasive Lineage Transition and Therapeutic Opportunities.
    Clin Cancer Res. 2021;27:5939-5950.
    PubMed     Abstract available
    
    
    October 2021
57. MEHTA S, Fiorelli R, Bao X, Pennington-Krygier C, et al
    A Phase 0 Trial of Ceritinib in Patients with Brain Metastases and Recurrent Glioblastoma.
    Clin Cancer Res. 2021 Oct 26. pii: 1078-0432.CCR-21-1096.
    PubMed     Abstract available
    
    
    
58. GAVRIELATOU N, Liu Y, Vathiotis I, Zugazagoitia J, et al
    Association of PD-1/PD-L1 Co-location with Immunotherapy Outcomes in Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2021 Oct 22. pii: 1078-0432.CCR-21-2649.
    PubMed     Abstract available
    
    
    September 2021
59. KAWAZOE A, Itahashi K, Yamamoto N, Kotani D, et al
    TAS-116 plus nivolumab in patients with colorectal cancer and other solid tumors: an, open-label, dose-finding, and expansion phase Ib trial (EPOC1704).
    Clin Cancer Res. 2021 Sep 30. pii: 1078-0432.CCR-21-1929.
    PubMed     Abstract available
    
    
    
60. PORCIUNCULA A, Morgado M, Gupta R, Syrigos K, et al
    Spatial mapping and immunomodulatory role of the OX40/OX40L pathway in human non-small cell lung cancer.
    Clin Cancer Res. 2021 Sep 13. pii: 1078-0432.CCR-21-0987.
    PubMed     Abstract available
    
    
    August 2021
61. SHI J, Wang Z, Zhang J, Xu Y, et al
    Genomic landscape and tumor mutational burden determination of circulating tumor DNA in over 5,000 Chinese lung cancer patients.
    Clin Cancer Res. 2021 Aug 26. pii: 1078-0432.CCR-21-1537.
    PubMed     Abstract available
    
    
    
62. CAMIDGE DR, Morgensztern D, Heist RS, Barve M, et al
    Phase 1 Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients With Advanced Non-Small Cell Lung Carcinoma.
    Clin Cancer Res. 2021 Aug 23. pii: 1078-0432.CCR-21-0765.
    PubMed     Abstract available
    
    
    
63. MAITLAND ML, Sachdev JC, Sharma MR, Moreno V, et al
    First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors.
    Clin Cancer Res. 2021;27:4511-4520.
    PubMed     Abstract available
    
    
    
64. SUZUKI S, Yonesaka K, Teramura T, Takehara T, et al
    KRAS inhibitor-resistance in MET-amplified KRAS (G12C) non-small cell lung cancer induced by RAS- and non-RAS-mediated cell signaling mechanisms.
    Clin Cancer Res. 2021 Aug 7. pii: 1078-0432.CCR-21-0856.
    PubMed     Abstract available
    
    
    
65. SUBBIAH V, Gainor JF, Oxnard GR, Tan DSW, et al
    Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancers on the LIBRETTO-001 Trial.
    Clin Cancer Res. 2021;27:4160-4167.
    PubMed     Abstract available
    
    
    
66. KIM SY, Kim SM, Lim S, Lee JY, et al
    Modeling Clinical Responses to Targeted Therapies by Patient-Derived Organoids of Advanced Lung Adenocarcinoma.
    Clin Cancer Res. 2021;27:4397-4409.
    PubMed     Abstract available
    
    
    
67. CONFORTI F, Pala L, Pagan E, Bagnardi V, et al
    Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion.
    Clin Cancer Res. 2021;27:4311-4324.
    PubMed     Abstract available
    
    
    July 2021
68. NAKAGAWA K, Nadal E, Garon EB, Nishio M, et al
    RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non-small Cell Lung Cancer.
    Clin Cancer Res. 2021 Jul 22. pii: 1078-0432.CCR-21-0273.
    PubMed     Abstract available
    
    
    
69. KOCH AL, Vellanki PJ, Drezner N, Li X, et al
    FDA Approval Summary: Osimertinib for adjuvant treatment of surgically resected non-small cell lung cancer, a collaborative Project Orbis review.
    Clin Cancer Res. 2021 Jul 22. pii: 1078-0432.CCR-21-1034.
    PubMed     Abstract available
    
    
    
70. CHANG JC, Offin M, Falcon C, Brown D, et al
    Comprehensive Molecular and Clinicopathologic Analysis of 200 Pulmonary Invasive Mucinous Adenocarcinomas Identifies Distinct Characteristics of Molecular Subtypes.
    Clin Cancer Res. 2021;27:4066-4076.
    PubMed     Abstract available
    
    
    
71. LUO J, Martucci VL, Quandt Z, Groha S, et al
    Immunotherapy-mediated thyroid dysfunction: genetic risk and impact on outcomes with PD-1 blockade in non-small cell lung cancer.
    Clin Cancer Res. 2021 Jul 8. pii: 1078-0432.CCR-21-0921.
    PubMed     Abstract available
    
    
    
72. FOSTER JH, Voss SD, Hall DC, Minard CG, et al
    Activity of Crizotinib in Patients with ALK-Aberrant Relapsed/Refractory Neuroblastoma: A Children's Oncology Group Study (ADVL0912).
    Clin Cancer Res. 2021;27:3543-3548.
    PubMed     Abstract available
    
    
    June 2021
73. WEISS SA, Djureinovic D, Jessel S, Krykbaeva I, et al
    A phase I study of APX005M and cabiralizumab with/without nivolumab in patients with melanoma, kidney cancer or non-small cell lung cancer resistant to anti-PD-(L)1.
    Clin Cancer Res. 2021 Jun 17. pii: 1078-0432.CCR-21-0903.
    PubMed     Abstract available
    
    
    
74. RAGHAV K, Hwang H, Jacome AA, Bhang E, et al
    Development and Validation of a Novel Nomogram for Individualized Prediction of Survival in Cancer of Unknown Primary.
    Clin Cancer Res. 2021;27:3414-3421.
    PubMed     Abstract available
    
    
    
75. GARON EB, Spira AI, Johnson M, Bazhenova L, et al
    A phase 1b open-label, multicenter study of inhaled DV281, a TLR9 agonist, in combination with nivolumab in patients with advanced or metastatic non-small cell lung cancer.
    Clin Cancer Res. 2021 Jun 9. pii: 1078-0432.CCR-21-0263.
    PubMed     Abstract available
    
    
    
76. LEWIS CD, Singh AK, Hsu FF, Thotala D, et al
    Targeting a Radiosensitizing Antibody-Drug Conjugate to a Radiation-Inducible Antigen.
    Clin Cancer Res. 2021;27:3224-3233.
    PubMed     Abstract available
    
    
    
77. COMPTE M, Harwood SL, Erce-Llamazares A, Tapia-Galisteo A, et al
    An Fc-free EGFR-specific 4-1BB-agonistic Trimerbody Displays Broad Antitumor Activity in Humanized Murine Cancer Models without Toxicity.
    Clin Cancer Res. 2021;27:3167-3177.
    PubMed     Abstract available
    
    
    May 2021
78. KIM J, Bradford D, Larkins E, Pai-Scherf LH, et al
    FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid cancers with RET gene mutations or fusions.
    Clin Cancer Res. 2021 May 27. pii: 1078-0432.CCR-21-0967.
    PubMed     Abstract available
    
    
    
79. CORTOT AB, Madroszyk-Flandin A, Giroux Leprieur E, Molinier O, et al
    First-line Afatinib plus Cetuximab for EGFR-mutant Non-small-cell Lung Cancer: Results from the Randomized Phase 2 IFCT-1503 ACE-Lung Study.
    Clin Cancer Res. 2021 May 24. pii: 1078-0432.CCR-20-4604.
    PubMed     Abstract available
    
    
    
80. CHOUDHURY NJ, Schoenfeld AJ, Flynn J, Falcon CJ, et al
    Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with EGFR Exon 20 Insertions.
    Clin Cancer Res. 2021;27:2920-2927.
    PubMed     Abstract available
    
    
    
81. BYERS LA, Bentsion D, Gans S, Penkov K, et al
    Veliparib in Combination with Carboplatin and Etoposide in Patients with Treatment-Naive Extensive-Stage Small Cell Lung Cancer: A Phase 2 Randomized Study.
    Clin Cancer Res. 2021 May 4. pii: 1078-0432.CCR-20-4259.
    PubMed     Abstract available
    
    
    
82. JONES GD, Caso R, Tan KS, Mastrogiacomo B, et al
    KRAS (G12C) Mutation Is Associated with Increased Risk of Recurrence in Surgically Resected Lung Adenocarcinoma.
    Clin Cancer Res. 2021;27:2604-2612.
    PubMed     Abstract available
    
    
    April 2021
83. CHEN K, Nie Y, Park S, Zhang K, et al
    Development and Validation of Machine Learning-based Model for the Prediction of Malignancy in Multiple Pulmonary Nodules: Analysis from Multicentric Cohorts.
    Clin Cancer Res. 2021;27:2255-2265.
    PubMed     Abstract available
    
    
    
84. OEHL K, Vrugt B, Wagner U, Kirschner MB, et al
    Alterations in BAP1 Are Associated with Cisplatin Resistance through Inhibition of Apoptosis in Malignant Pleural Mesothelioma.
    Clin Cancer Res. 2021;27:2277-2291.
    PubMed     Abstract available
    
    
    
85. DREYFUSS AD, Goia D, Shoniyozov K, Shewale SV, et al
    A Novel Mouse Model of Radiation-Induced Cardiac Injury Reveals Biological and Radiological Biomarkers of Cardiac Dysfunction with Potential Clinical Relevance.
    Clin Cancer Res. 2021;27:2266-2276.
    PubMed     Abstract available
    
    
    
86. SHAFIQUE M, Fisher TL, Evans EE, Leonard JE, et al
    A Phase 1b/2 Study of Pepinemab in Combination with Avelumab in Advanced Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2021 Apr 5. pii: 1078-0432.CCR-20-4792.
    PubMed     Abstract available
    
    
    March 2021
87. BERTINO EM, Gentzler RD, Clifford S, Kolesar J, et al
    Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903).
    Clin Cancer Res. 2021;27:1604-1611.
    PubMed     Abstract available
    
    
    
88. SI H, Kuziora M, Quinn KJ, Helman E, et al
    A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study.
    Clin Cancer Res. 2021;27:1631-1640.
    PubMed     Abstract available
    
    
    
89. SITTHIDEATPHAIBOON P, Galan-Cobo A, Negrao MV, Qu X, et al
    STK11/LKB1 Mutations in NSCLC Are Associated with KEAP1/NRF2-Dependent Radiotherapy Resistance Targetable by Glutaminase Inhibition.
    Clin Cancer Res. 2021;27:1720-1733.
    PubMed     Abstract available
    
    
    
90. LIN JJ, Choudhury NJ, Yoda S, Zhu VW, et al
    Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion-Positive Lung Cancer.
    Clin Cancer Res. 2021 Mar 8. pii: 1078-0432.CCR-21-0032.
    PubMed     Abstract available
    
    
    
91. AGGARWAL C, Thompson JC, Carpenter EL
    Plasma Tumor Mutation Burden and Response to Pembrolizumab-Response.
    Clin Cancer Res. 2021;27:1581.
    PubMed    
    
    
    
92. XUE Z, Guo X, Wen J, Cai W, et al
    Plasma Tumor Mutation Burden and Response to Pembrolizumab-Letter.
    Clin Cancer Res. 2021;27:1580.
    PubMed    
    
    
    
93. ESTRADA-BERNAL A, Le AT, Doak AE, Tirunagaru VG, et al
    Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes.
    Clin Cancer Res. 2021;27:1463-1475.
    PubMed     Abstract available
    
    
    
94. HACKENG WM, Dreijerink KMA, de Leng WWJ, Morsink FHM, et al
    Genome Methylation Accurately Predicts Neuroendocrine Tumor Origin: An Online Tool.
    Clin Cancer Res. 2021;27:1341-1350.
    PubMed     Abstract available
    
    
    
95. ZHOU C, Wang Y, Zhao J, Chen G, et al
    Efficacy and Biomarker Analysis of Camrelizumab in Combination with Apatinib in Patients with Advanced Nonsquamous NSCLC Previously Treated with Chemotherapy.
    Clin Cancer Res. 2021;27:1296-1304.
    PubMed     Abstract available
    
    
    
96. TANIMOTO A, Matsumoto S, Takeuchi S, Arai S, et al
    Proteasome Inhibition Overcomes ALK-TKI Resistance in ALK-Rearranged/TP53-Mutant NSCLC via Noxa Expression.
    Clin Cancer Res. 2021;27:1410-1420.
    PubMed     Abstract available
    
    
    February 2021
97. VELLANKI PJ, Mulkey F, Jaigirdar AA, Rodriguez L, et al
    FDA Approval Summary: Nivolumab with Ipilimumab and Chemotherapy for Metastatic Non-Small Cell Lung Cancer, a Collaborative Project Orbis Review.
    Clin Cancer Res. 2021 Feb 25. pii: 1078-0432.CCR-20-4338.
    PubMed     Abstract available
    
    
    
98. DATAR IJ, Hauc S, Desai SS, Gianino N, et al
    Spatial analysis and clinical significance of HLA class-I and class-II subunit expression in non-small cell lung cancer.
    Clin Cancer Res. 2021 Feb 18. pii: 1078-0432.CCR-20-3655.
    PubMed     Abstract available
    
    
    
99. SKWARSKI M, McGowan DR, Belcher E, Di Chiara F, et al
    Mitochondrial Inhibitor Atovaquone Increases Tumor Oxygenation and Inhibits Hypoxic Gene Expression in Patients with Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2021 Feb 17. pii: 1078-0432.CCR-20-4128.
    PubMed     Abstract available
    
    
    
100. GARON EB
     Osimertinib plus Ramucirumab: The Best of Both Worlds?
     Clin Cancer Res. 2021;27:905-907.
     PubMed     Abstract available
     
     
     
101. SKOULIDIS F
     Transcription Strikes Back: Clinical Utility of Lung Adenocarcinoma Subtypes.
     Clin Cancer Res. 2021;27:913-915.
     PubMed     Abstract available
     
     
     
102. HELLMANN MD, Janne PA, Opyrchal M, Hafez N, et al
     Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Anti-PD-(L)1 Therapy.
     Clin Cancer Res. 2021;27:1019-1028.
     PubMed     Abstract available
     
     
     
103. TAN Y, Sementino E, Cheung M, Peri S, et al
     Somatic Epigenetic Silencing of RIPK3 Inactivates Necroptosis and Contributes to Chemoresistance in Malignant Mesothelioma.
     Clin Cancer Res. 2021;27:1200-1213.
     PubMed     Abstract available
     
     
     
104. DAEMEN A, Cooper JE, Myrta S, Wongchenko MJ, et al
     Transcriptional Subtypes Resolve Tumor Heterogeneity and Identify Vulnerabilities to MEK Inhibition in Lung Adenocarcinoma.
     Clin Cancer Res. 2021;27:1162-1173.
     PubMed     Abstract available
     
     
     
105. HARVEY RD, Bruinooge SS, Chen L, Garrett-Mayer E, et al
     Impact of Broadening Trial Eligibility Criteria for Patients with Advanced Non-Small Cell Lung Cancer: Real-World Analysis of Select ASCO-Friends Recommendations.
     Clin Cancer Res. 2021 Feb 9. pii: 1078-0432.CCR-20-3857.
     PubMed     Abstract available
     
     
     
106. ARBOUR KC, Rizvi H, Plodkowski AJ, Hellmann MD, et al
     Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C Mutant Non-Small Cell Lung Cancer.
     Clin Cancer Res. 2021 Feb 8. pii: 1078-0432.CCR-20-4023.
     PubMed     Abstract available
     
     
     
107. AI X, Cui J, Zhang J, Chen R, et al
     Clonal Architecture of EGFR Mutation Predicts the Efficacy of EGFR-Tyrosine Kinase Inhibitors in Advanced NSCLC: A Prospective Multicenter Study (NCT03059641).
     Clin Cancer Res. 2021;27:704-712.
     PubMed     Abstract available
     
     
     
108. GUO R, Offin M, Brannon AR, Chang J, et al
     MET Exon 14-altered Lung Cancers and MET Inhibitor Resistance.
     Clin Cancer Res. 2021;27:799-806.
     PubMed     Abstract available
     
     
     January 2021
109. RAHMA OE, Reuss JE, Giobbie-Hurder A, Shoja E Razavi G, et al
     Early 3+3 Trial Dose-Escalation Phase I Clinical Trial Design and Suitability for Immune Checkpoint Inhibitors.
     Clin Cancer Res. 2021;27:485-491.
     PubMed     Abstract available
     
     
     
110. GEIGER T, Beck L, Harel M, Yu S, et al
     Clinical Proteomics of Metastatic Melanoma Reveals Profiles of Organ-Specificity and Treatment Resistance.
     Clin Cancer Res. 2021 Jan 14. pii: 1078-0432.CCR-20-3752.
     PubMed     Abstract available
     
     
     
111. DEUTSCH E, Chargari C, Weichselbaum RR, Levy A, et al
     Drug-Radiotherapy Combination Trial Developments-Response.
     Clin Cancer Res. 2021;27:356.
     PubMed    
     
     
     
112. EVANS JR, Cuneo KC, Lawrence TS
     Drug-Radiotherapy Combination Trial Developments-Letter.
     Clin Cancer Res. 2021;27:355.
     PubMed    
     
     
     
113. COLCLOUGH N, Chen K, Johnstrom P, Strittmatter N, et al
     Preclinical Comparison of the Blood-brain barrier Permeability of Osimertinib with Other EGFR TKIs.
     Clin Cancer Res. 2021;27:189-201.
     PubMed     Abstract available
     
     
     December 2020
114. SINGH S, Jaigirdar AA, Mulkey F, Cheng J, et al
     FDA Approval Summary: Lurbinectedin for the Treatment of Metastatic Small Cell Lung Cancer.
     Clin Cancer Res. 2020 Dec 7. pii: 1078-0432.CCR-20-3901.
     PubMed     Abstract available
     
     
     
115. DE HAAN R, Van den Heuvel M, van Diessen J, Peulen HMU, et al
     Phase 1 and pharmacological study of olaparib in combination with high-dose radiotherapy with and without concurrent cisplatin for non-small cell lung cancer.
     Clin Cancer Res. 2020 Dec 1. pii: 1078-0432.CCR-20-2551.
     PubMed     Abstract available
     
     
     November 2020
116. BRADFORD D, Larkins E, Mushti SL, Rodriguez L, et al
     FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid cancers with RET Gene Mutations or Fusions.
     Clin Cancer Res. 2020 Nov 25. pii: 1078-0432.CCR-20-3558.
     PubMed     Abstract available
     
     
     
117. GIFFIN MJ, Cooke K, Lobenhofer EK, Estrada JC, et al
     AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small Cell Lung Cancer.
     Clin Cancer Res. 2020 Nov 17. pii: 1078-0432.CCR-20-2845.
     PubMed     Abstract available
     
     
     
118. SALAS-BENITO D, Eguren-Santamaria I, Sanmamed MF
     Senescent T-cells as a resistance mechanism to lung cancer immunotherapy.
     Clin Cancer Res. 2020 Nov 13. pii: 1078-0432.CCR-20-3507.
     PubMed     Abstract available
     
     
     October 2020
119. ROSEN EY, Johnson ML, Clifford SE, Somwar R, et al
     Overcoming MET-dependent resistance to selective RET inhibition in patients with RET fusion-positive lung cancer by combining selpercatinib with crizotinib.
     Clin Cancer Res. 2020 Oct 20. pii: 1078-0432.CCR-20-2278.
     PubMed     Abstract available
     
     
     
120. SINGH A, Daemen A, Nickles D, Jeon SM, et al
     NRF2 activation promotes aggressive lung cancer and associates with poor clinical outcomes.
     Clin Cancer Res. 2020 Oct 19. pii: 1078-0432.CCR-20-1985.
     PubMed     Abstract available
     
     
     
121. YU HA, Paz-Ares LG, Yang JC, Lee KH, et al
     Phase 1 Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-Positive EGFR-Mutant Non-Small Cell Lung Cancer.
     Clin Cancer Res. 2020 Oct 12. pii: 1078-0432.CCR-20-1690.
     PubMed     Abstract available
     
     
     September 2020
122. ADACHI Y, Ito K, Hayashi Y, Kimura R, et al
     Epithelial to mesenchymal transition is a cause of both intrinsic and acquired resistance to KRAS G12C inhibitor in KRAS G12C mutant non-small cell lung cancer.
     Clin Cancer Res. 2020 Sep 8. pii: 1078-0432.CCR-20-2077.
     PubMed     Abstract available
     
     
     
123. FERRARA R, Naigeon M, Auclin E, Duchemann B, et al
     Circulating T-cell immunosenescence in advanced non-small cell lung cancer patients treated with single agent PD-1/PD-L1 inhibitors or platinum-based chemotherapy.
     Clin Cancer Res. 2020 Sep 4. pii: 1078-0432.CCR-20-1420.
     PubMed     Abstract available
     
     
     August 2020
124. ORTIZ-CUARAN S, Mezquita L, Swalduz A, Aldea M, et al
     Circulating tumor DNA genomics reveals potential mechanisms of resistance to BRAF-targeted therapies in BRAF-mutant metastatic non-small cell lung cancer patients.
     Clin Cancer Res. 2020 Aug 28. pii: 1078-0432.CCR-20-1037.
     PubMed     Abstract available
     
     
     
125. GERBER DE, Putnam WC, Fattah FJ, Kernstine KH, et al
     Concentration-dependent early anti-vascular and anti-tumor effects of itraconazole in non-small cell lung cancer.
     Clin Cancer Res. 2020 Aug 26. pii: 1078-0432.CCR-20-1916.
     PubMed     Abstract available
     
     
     
126. XING L, Pan Y, Shi Y, Shu Y, et al
     Biomarkers of osimertinib response in patients with refractory, EGFR-T790M-positive non-small cell lung cancer and central nervous system metastases:the APOLLO study.
     Clin Cancer Res. 2020 Aug 17. pii: 1078-0432.CCR-20-2081.
     PubMed     Abstract available
     
     
     July 2020
127. MADAJEWSKI B, Chen F, Yoo B, Turker MZ, et al
     Molecular Engineering of Ultrasmall Silica Nanoparticle-Drug Conjugates as Lung Cancer Therapeutics.
     Clin Cancer Res. 2020 Jul 28. pii: 1078-0432.CCR-20-0851.
     PubMed     Abstract available
     
     
     
128. SCHOENFELD AJ, Bandlamudi C, Lavery JA, Montecalvo J, et al
     The Genomic Landscape of SMARCA4 Alterations and Associations with Outcomes in Patients with Lung Cancer.
     Clin Cancer Res. 2020 Jul 24. pii: 1078-0432.CCR-20-1825.
     PubMed     Abstract available
     
     
     
129. BLAKELY CM, McCoach CE
     Role of MPR as an Early Signal for Efficacy in Neoadjuvant Studies.
     Clin Cancer Res. 2020;26:3499-3500.
     PubMed     Abstract available
     
     
     
130. MULLER M, Hummelink K, Hurkmans DP, Niemeijer AN, et al
     A serum protein classifier identifying patients with advanced non-small cell lung cancer who derive clinical benefit from treatment with immune checkpoint inhibitors.
     Clin Cancer Res. 2020 Jul 6. pii: 1078-0432.CCR-20-0538.
     PubMed     Abstract available
     
     
     
131. AGGARWAL C, Thompson JC, Carpenter EL
     Plasma Tumor Mutation Burden and Response to Pembrolizumab-Response.
     Clin Cancer Res. 2020;26:3492.
     PubMed    
     
     
     
132. LI X, Xu Y, Wang G, Li L, et al
     Plasma Tumor Mutation Burden and Response to Pembrolizumab-Letter.
     Clin Cancer Res. 2020;26:3491.
     PubMed    
     
     
     
133. GOERIG NL, Frey B, Korn K, Fleckenstein B, et al
     Early Mortality of Brain Cancer Patients and its Connection to Cytomegalovirus Reactivation During Radiochemotherapy.
     Clin Cancer Res. 2020;26:3259-3270.
     PubMed     Abstract available
     
     
     June 2020
134. HIPP S, Voynov V, Drobits-Handl B, Giragossian C, et al
     A Bispecific DLL3/CD3 IgG-like T-cell Antibody induces anti-tumor responses in Small Cell Lung Cancer.
     Clin Cancer Res. 2020 Jun 18. pii: 1078-0432.CCR-20-0926.
     PubMed     Abstract available
     
     
     
135. VAN DEN BROECK A, Brambilla E, Moro-Sibilot D, Lantuejoul S, et al
     Correction: Loss of Histone H4K20 Trimethylation Occurs in Preneoplasia and Influences Prognosis of Non-Small Cell Lung Cancer.
     Clin Cancer Res. 2020;26:2768.
     PubMed    
     
     
     
136. VAN DEN BROECK A, Brambilla E, Moro-Sibilot D, Lantuejoul S, et al
     Correction: Editor's Note: Loss of Histone H4K20 Trimethylation Occurs in Preneoplasia and Influences Prognosis of Non-Small Cell Lung Cancer.
     Clin Cancer Res. 2020;26:2767.
     PubMed    
     
     
     
137. PIOTROWSKA Z, Hata AN
     Resistance to First-line Osimertinib in EGFR-mutant NSCLC: Tissue is the Issue.
     Clin Cancer Res. 2020;26:2441-2443.
     PubMed     Abstract available
     
     
     May 2020
138. LIU B, Ricarte-Filho J, Mallisetty A, Villani C, et al
     Detection of promoter DNA methylation in urine and plasma aids the detection of non-small cell lung cancer.
     Clin Cancer Res. 2020 May 19. pii: 1078-0432.CCR-19-2896.
     PubMed     Abstract available
     
     
     
139. BAGLEY SJ, Carpenter EL
     Plasma cfDNA in Glioblastoma-Response.
     Clin Cancer Res. 2020;26:2276.
     PubMed    
     
     
     
140. GLITZA OLIVA IC, Tawbi HA
     "Liquid Gold" - The unTAPped Potential of Cerebrospinal Fluid Analysis?
     Clin Cancer Res. 2020;26:2083-2084.
     PubMed     Abstract available
     
     
     April 2020
141. EGUREN-SANTAMARIA I, Sanmamed MF, Goldberg SB, Kluger HM, et al
     PD-1/PD-L1 blockers in NSCLC brain metastases: challenging paradigms and clinical practice.
     Clin Cancer Res. 2020 Apr 30. pii: 1078-0432.CCR-20-0798.
     PubMed     Abstract available
     
     
     
142. RICCIUTI B, Recondo G, Spurr LF, Li YY, et al
     Impact of DNA damage response and repair (DDR) gene mutations on efficacy of PD-(L)1 immune checkpoint inhibition in non-small cell lung cancer.
     Clin Cancer Res. 2020 Apr 24. pii: 1078-0432.CCR-19-3529.
     PubMed     Abstract available
     
     
     
143. COOPER AJ, Kobayashi Y, Kim D, Clifford SE, et al
     Identification of a RAS-activating TMEM87A-RASGRF1 fusion in an exceptional responder to sunitinib with non-small cell lung cancer.
     Clin Cancer Res. 2020 Apr 20. pii: 1078-0432.CCR-20-0397.
     PubMed     Abstract available
     
     
     
144. PAIK PK, Kim RK, Ahn L, Plodkowski AJ, et al
     A Phase II Trial of Albumin-Bound Paclitaxel and Gemcitabine in Patients with Newly Diagnosed Stage IV Squamous Cell Lung Cancers.
     Clin Cancer Res. 2020;26:1796-1802.
     PubMed     Abstract available
     
     
     
145. YUN MR, Kim DH, Kim SY, Joo HS, et al
     Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naive and Solvent-Front-Mutant ROS1-Rearranged Non-Small Cell Lung Cancer.
     Clin Cancer Res. 2020 Apr 8. pii: 1078-0432.CCR-19-2777.
     PubMed     Abstract available
     
     
     
146. ZUGAZAGOITIA J, Gupta S, Liu Y, Fuhrman K, et al
     Biomarkers associated with beneficial PD-1 checkpoint blockade in non-small-cell lung cancer (NSCLC) identified using high-plex digital spatial profiling.
     Clin Cancer Res. 2020 Apr 6. pii: 1078-0432.CCR-20-0175.
     PubMed     Abstract available
     
     
     
147. VAN DEN BROECK A, Brambilla E, Moro-Sibilot D, Lantuejoul S, et al
     Editor's Note: Loss of Histone H4K20 Trimethylation Occurs in Preneoplasia and Influences Prognosis of Non-Small Cell Lung Cancer.
     Clin Cancer Res. 2020;26:1776.
     PubMed    
     
     
     
148. LANDI L, Bruno R, Fontanini G, Cappuzzo F, et al
     Crizotinib in ROS1 and MET Deregulated NSCLC-Response.
     Clin Cancer Res. 2020;26:1775.
     PubMed    
     
     
     
149. WIESWEG M, Schuler M, Schildhaus HU
     Crizotinib in ROS1 and MET Deregulated NSCLC-Letter.
     Clin Cancer Res. 2020;26:1774.
     PubMed    
     
     
     
150. YAEGER R, Solit DB
     Overcoming Adaptive Resistance to KRAS Inhibitors Through Vertical Pathway Targeting.
     Clin Cancer Res. 2020;26:1538-1540.
     PubMed     Abstract available
     
     
     March 2020
151. HENICK BS
     Elite Intratumoral T-cell Clonotypes (The 1%) Effect "Trickle-Down Cytotoxicity".
     Clin Cancer Res. 2020;26:1205-1207.
     PubMed     Abstract available
     
     
     
152. CHUNG JS, Ramani V, Kobayashi M, Fattah F, et al
     DC-HIL/Gpnmb Is a Negative Regulator of Tumor Response to Immune Checkpoint Inhibitors.
     Clin Cancer Res. 2020;26:1449-1459.
     PubMed     Abstract available
     
     
     February 2020
153. ZHUO M, Guan Y, Yang X, Hong L, et al
     The Prognostic and Therapeutic Role of Genomic Subtyping by Sequencing Tumor or Cell-Free DNA in Pulmonary Large-Cell Neuroendocrine Carcinoma.
     Clin Cancer Res. 2020;26:892-901.
     PubMed     Abstract available
     
     
     
154. LIU Y, Zugazagoitia J, Ahmed FS, Henick BS, et al
     Immune Cell PD-L1 Colocalizes with Macrophages and Is Associated with Outcome in PD-1 Pathway Blockade Therapy.
     Clin Cancer Res. 2020;26:970-977.
     PubMed     Abstract available
     
     
     January 2020
155. POCHA K, Mock A, Rapp C, Dettling S, et al
     Surfactant expression defines an inflamed subtype of lung adenocarcinoma brain metastases that correlates with prolonged survival.
     Clin Cancer Res. 2020 Jan 17. pii: 1078-0432.CCR-19-2184.
     PubMed     Abstract available
     
     
     
156. DI FEDERICO A, Filippini DM, Dall'Olio FG, Conci N, et al
     The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma-Letter.
     Clin Cancer Res. 2020;26:518-519.
     PubMed    
     
     
     
157. KIM BH, Kim YJ, Kim MH, Na YR, et al
     Identification of FES as a Novel Radiosensitizing Target in Human Cancers.
     Clin Cancer Res. 2020;26:265-273.
     PubMed     Abstract available
     
     
     October 2019
158. YANG Y, Yang H, Tang B, Wu AML, et al
     The outcome of TGFbeta antagonism in metastatic breast cancer models in vivo reflects a complex balance between tumor-suppressive and pro-progression activities of TGFbeta.
     Clin Cancer Res. 2019 Oct 3. pii: 1078-0432.CCR-19-2370.
     PubMed     Abstract available
     
     
     April 2019
159. ZHANG J, Chen J, Wo D, Yan H, et al
     LRP6 ectodomain prevents SDF-1/CXCR4-induced breast cancer metastasis to lung.
     Clin Cancer Res. 2019 Apr 22. pii: 1078-0432.CCR-18-3557.
     PubMed     Abstract available
     
     
     February 2019
160. JEONG MH, Park SY, Lee SH, Seo J, et al
     EPB41L5 mediates TGF--induced metastasis of gastric cancer.
     Clin Cancer Res. 2019 Feb 27. pii: 1078-0432.CCR-18-2959.
     PubMed     Abstract available
     
     
     
161. WANG X, Liang JQ, Zhang LH, Gou H, et al
     C8orf76 promotes gastric tumorigenicity and metastasis by directly inducing lncRNA DUSP5P1 and associates with patient outcomes.
     Clin Cancer Res. 2019 Feb 7. pii: 1078-0432.CCR-18-2804.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: